The present invention provides chimeric and humanized versions of anti-CD22mouse monoclonal antibody, HB22.7. The anti-CD22 antibodies of the inventioncomprise four human or humanized framework regions of the immunoglobulin heavychain variable region ("VH") and four human or humanized frameworkregions of the immunoglobulin light chain variable region ("VK").The invention further comprises heavy and/or light chain FW regions that containone or more backmutations in which a human FW residue is exchanged for the correspondingresidue present in the parental mouse heavy or light chain. Human or humanizedVH framework regions of antibodies of the invention may comprise one or more ofthe following residues: a valine (V) at position 24 of framework region 1, a glycine(G) at position 49 of framework region 2, and an asparagine (N) at position 73 offramework region 3, numbered according to Kabat. The invention further relatesto pharmaceutical compositions, immunotherapeutic compositions, and methodsusing therapeutic antibodies that bind to the human CD22 antigen and that preferablymediate human ADCC, CDC, and/or apoptosis for: the treatment of B cell diseasesand disorders in human subjects, such as, but not limited to, B cell malignancies,for the treatment and prevention of autoimmune disease, and for the treatmentand prevention of graft- versus-host disease (GVHD), humoral rejection, andpost-transplantation lymphoproliferative disorder in human transplant recipients.
